 |
인쇄하기
취소
|
Choong-wae to conduct Phase 3 trial over new biological therapy, Actemra
Choong-wae Pharm said on June 17 that the Korea Food and Drug Administration has approved Phase 3 study of Actemra (tocilizumab), to treat patients with rheumatoid arthritis (RA).
The company entered into an exclusive license agreement with Chugai to develop, market, sell and distribute Actemra in Korea in March.
Choong-wae plans to launch Acetemra in 2012 after completion of the local cl...
The company entered into an exclusive license agreement with Chugai to develop, market, sell and distribute Actemra in Korea in March.
Choong-wae plans to launch Acetemra in 2012 after completion of the local cl...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.